Companies › CellTrans
1 active drug program in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Basiliximab Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00679042 | Basiliximab | Phase 3 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Jul 2017 |
| NCT05139004 | Basiliximab | Phase 1 | Acute Lymphoblastic Leukemia | Oncology | Jun 2027 |
| NCT04871607 | Basiliximab | Phase 2 | Recurrent Hodgkin Lymphoma | Oncology | Oct 2029 |
| NCT05385432 | Basiliximab | Phase 3 | Renal Transplant Rejection | Genitourinary | Dec 2030 |
AgonOx Sanofi ImmunityBio Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG GI Innovation Synthekine
HealthTech Wound Care PolarityTE Royal Biologics Innovacell Ascendis Pharma Bone Diseases
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.